,,iv  #aag? ,,congress  #a/ ,session    
,h4 ,,res4 #efc  ,,9 ,,! ,,h\se ,,(     
,,repres5tatives  ,july #bg1 #bjba,ms4  
,m5g 7= h]self1 ,mr4 ,johnson (         
,georgia1 ,mr4 ,fitzpatrick1 ,ms4       
,velzquez1 & ,ms4 ,*u7 submitt$ ! foll[+
 resolution2 :i* 0 ref]r$ to !          
,committee on ,en]gy & ,comm]ce         
,,resolution  ,recogniz+ ,july #bh1     
#bjba1 z ,_w ,hepatitis ,day4  ,:]eas   
hepatitis ,b & hepatitis ,c1 & !        
incid5ce ( liv] disease caus$ by ^!     
viruses1 h become urg5t problems ( a    
global proportion2 ,:]eas an e/imat$    
#a1cdj1jjj p worldwide die ea* ye> due  
to hepatitis2 ,:]eas an e/imat$         
#bib1jjj1jjj p worldwide live ) *ronic  
hepatitis ,b1 & an e/imat$ #hhd1jjj p   
worldwide die ea* ye> mo/ly due to a    
liv]-relat$ illness caus$ by hepatitis  
,b2 ,:]eas an e/imat$ #ga1jjj1jjj p     
worldwide are *ronically infect$ )      
hepatitis ,c1 & an e/imat$ #cii1jjj p   
worldwide die ea* ye> due to a          
liv]-relat$ illness caus$ by hepatitis  

,c2 ,:]eas up to an e/imat$ #e1ijj1jjj p
 9 ! ,unit$ ,/ates are infect$ ) ei!r   
hepatitis ,b or hepatitis ,c1 & up to an
 e/imat$ #b1djj1jjj :o are *ronically   
infect$ ) hepatitis ,b & up to an       
e/imat$ #c1ejj1jjj p :o are *ronically  
infect$ ) hepatitis ,c2 ,:]eas ! ,c5t]s 
= ,disease ,control & ,prev5tion 7,,cdc7
 e/imat$ t !re 7 #bj1gjj new acute      
hepatitis ,b infections & #eg1ejj new   
acute hepatitis ,c infections1          
respectively1 9 ! ,unit$ ,/ates 9 #bjai2
 ,:]eas ! ,,cdc has f\nd significant    
increases 9 ! transmission ( new        
hepatitis cases 9 ! ,unit$ ,/ates s9ce  
#bjaj1 includ+ a #fc-p]c5t increase     
betwe5 #bjae & #bjai 9 report$ cases (  
acute hepatitis ,c 9 ! ,unit$ ,/ates2   
,:]eas *ronic viral hepatitis claims    
?\s&s ( lives ea* ye> 9 ! ,unit$ ,/ates1
 ) an e/imat$ #ad1bdb dea?s due to      
hepatitis ,c 9 ! ,unit$ ,/ates 9 #bjaf2 
,:]eas up to an e/imat$ #hj p]c5t ( p ) 
acute hepatitis ,c d n h any symptoms2  
,:]eas available data sugge/s t m ?an   

#gj p]c5t ( new hepatitis ,c infections 
& #cf p]c5t ( new hepatitis ,b          
infections are among p :o inject drugs2 
,:]eas ,african ,am]icans1 ,asian       
,am]icans1 ,pacific ,isl&]s1 ,lat9os1   
,native ,am]icans1 ,alaska ,natives1 gay
 & bisexual m51 & p]sons :o inject drugs
 intrav5\sly all h high] rates ( *ronic 
viral hepatitis infections 9 ! ,unit$   
,/ates ?an o!r gr\ps ( p2 ,:]eas ,asian 
,am]icans & ,pacific ,isl&]s be> !      
greate/ burd5 ( hepatitis ,b-relat$     
dea?s 9 ! ,unit$ ,/ates2 ,:]eas betwe5  
#bjac & #bjag1 liv] canc] 0 ! second mo/
 common cause ( dea? among ,asian       
,am]ican & ,pacific ,isl&] males2 ,:]eas
 hepatitis ,c is #aj times m infecti\s  
?an human immunodefici5cy virus 7,,hiv72
 ,:]eas hepatitis ,b is #ej to #ajj     
times m infecti\s ?an ,,hiv2 ,:]eas an  
e/imat$ #cc p]c5t ( p :o live 9 ! ,unit$
 ,/ates & are infect$ ) ,,hiv are also  
infect$ ) hepatitis ,b or ,c2 ,:]eas    
life expectancies = p]sons infect$ )    
,,hiv h increas$ ) antiretroviral       

treatm5t1 & liv] disease1 mu* ( :i* is  
relat$ to hepatitis ,b & hepatitis ,c   
infections1 has become ! mo/ common     
cause ( dea? among ?is population t is n
 relat$ to acquir$ immune defici5cy     
syndrome2 ,:]eas despite ! fact t *ronic
 viral hepatitis is ! mo/ common        
blood-borne infection 9 ! ,unit$ ,/ates1
 ov] half ( p liv+ ) hepatitis ,b &     
hepatitis ,c are unaw>e ( _! infection2 
,:]eas hepatitis ,b is prev5table ?r\gh 
vacc9ation1 & bo? hepatitis ,b &        
hepatitis ,c are prev5table ) prop]     
public heal? int]v5tions1 includ+       
programs t (f] access to /]ile injection
 equipm5t = p :o inject drugs           
intrav5\sly2 ,:]eas ! ,,cdc has labell$ 
viral hepatitis a ,w9nable ,battle1 a   
public heal? priority1 :]e ! ,,cdc & its
 p>tn]s c make significant progress end+
 epidemics & elim9at+ diseases to help  
advance ! ,,cdc ,/rategic ,framework 9 a
 relatively %ort "t frame2 ,:]eas !     
,dep>tm5t ( ,heal? & ,human ,s]vices has
 releas$ an updat$ ,viral ,hepatitis    

,national ,/rategic ,plan focus$ on !   
elim9ation ( viral hepatitis via a      
syndemic approa* by prev5t+ new         
infections1 improv+ viral               
hepatitis-relat$ heal? outcomes1 r$uc+  
viral hepatitis-relat$ disp>ities &     
heal? inequities1 improv+ surveillance &
 data usage1 & coord9at+ su* ef=ts2     
,:]eas ! ,,covid-#ai global p&emic has  
exac]bat$ public heal? *all5ges1 includ+
 viral hepatitis prev5tion1 c>e1 &      
treatm5t2 ,:]eas1 z a result (          
,,covid-#ai1 hepatitis s]vices h be5    
significantly r$uc$1 & community-bas$   
organizations h _h to r$uce op]ations1  
sev]ely r$uc+ hepatitis ,b & ,c te/+1   
hepatitis ,b vacc9ation1 & community    
outrea*2 ,:]eas1 z a result (           
,,covid-#ai1 p]sons liv+ ) hepatitis ,b 
or ,c h fac$ increas$ *all5ges 9 access+
 m$ical c>e & treatm5t due to delay$    
appo9tm5ts & de-prioritization ( r\t9e  
hepatitis or prim>y c>e s]vices2 &      
,:]eas ! goals ( ,_w ,hepatitis ,day on 
,july #bh1 #bjba1 are to-- 7#a7         

highlight ! global nature ( *ronic viral
 hepatitis epidemics2  7#b7 recognize t 
hepatitis c be prev5t$ & elim9at$ 9 "p  
?r\gh a compreh5sive public education & 
aw>5ess campaign design$ to id5tify ^?  
at risk =1 & liv+ )1 hepatitis2  7#c7   
in=m pati5ts ab\t new treatm5ts t are   
available = hepatitis2 &  7#d7 help     
increase ! l5g? & quality ( life = p    
diagnos$ ) *ronic hepatitis ,b &        
hepatitis ,c infections3 ,n[1 !re=e1 be 
x  ,t ! ,h\se ( ,repres5tatives-- 7#a7  
recognizes ,_w ,hepatitis ,day2  7#b7   
supports broad access to hepatitis ,b & 
hepatitis ,c treatm5ts2  7#c7 supports  
rais+ aw>5ess ( ! risks & consequ5ces ( 
undiagnos$ *ronic hepatitis ,b &        
hepatitis ,c infections2 &  7#d7 calls =
 a robu/ gov]nm5tal & public heal?      
response to protect ! heal? ( !         
approximately #e1ijj1jjj p 9 ! ,unit$   
,/ates4